- Trial phase
- Filed/PDUFA
- Time to market
- Approved product (Xulane) already on market since 2014. XULANE LO (low-dose version) PDUFA decision July 30, 2026, potential launch H2 2026 if approved.
- Why 6/10
- The next hard catalyst is the FDA PDUFA decision on XULANE LO (low-dose norelgestromin/ethinyl estradiol weekly patch) on July 30, 2026, roughly one month away. This is a binary regulatory decision on a Phase 3 drug that is a meaningful growth driver in Viatris's women's health pipeline, but Viatris is a large diversified pharma ($15B+ market cap, $14B+ annual revenue), so even a positive decision would drive a modest share-price move relative to the company's overall scale.
Watch the July 30, 2026 PDUFA date for XULANE LO. If approved, the low-estrogen positioning and "best-in-class adhesion" claims could help Viatris capture share in the ~$1B+ contraceptive patch market. A CRL (complete response letter) would be a near-term negative but not company-threatening given Viatris's diversified portfolio. The stock is near its 52-week high (~$17.53) with 12 sell-side analysts averaging a $17.81 target, suggesting modest upside is already priced in.
Price Chart
Executive Summary
Viatris (VTRS) markets Xulane, an FDA-approved weekly contraceptive patch (150/35 mcg per day), and has developed XULANE LO (MR-100A-01), a lower-estrogen version (150/17.5 mcg per day) currently under FDA review with a PDUFA date of July 30, 2026. Phase 3 data showed the low-dose patch met all endpoints with a Pearl Index of 4.14 and 3.7% cumulative pregnancy probability over 13 cycles. The lower estrogen dose targets the black-box warning concerns around the original Xulane (cardiovascular risk, particularly in smokers and women with BMI ≥ 30). The contraceptive patch is a niche but growing segment of the broader $14B+ global contraceptive market, with Xulane and Twirla as the main branded competitors. For Viatris, which generated $3.5B in Q1 2026 revenue alone, XULANE LO is one of several pipeline catalysts but not a make-or-break asset.
How It Works
This is a once-weekly birth control patch worn on the skin that releases two hormones (a progestin called norelgestromin and an estrogen called ethinyl estradiol) through the skin into the bloodstream to prevent pregnancy. The existing Xulane delivers 150 mcg norelgestromin and 35 mcg ethinyl estradiol per day; the investigational XULANE LO delivers the same amount of progestin but a lower 17.5 mcg daily dose of estrogen to potentially reduce cardiovascular risks.
Trial Status
Phase 3 study (NCT05139121) completed with positive topline results announced May 8, 2025, met primary and all secondary efficacy and safety endpoints. NDA accepted by FDA under 505(b)(2) pathway. PDUFA goal date set for July 30, 2026. Six data presentations at ACOG 2026 supported efficacy, adhesion, and pharmacokinetic profile.
The Two-Sided Case
Upcoming Catalysts
- PDUFA decision for XULANE LO (low-dose weekly contraceptive patch) on July 30, 2026.
- If approved, commercial launch trajectory and prescription adoption in H2 2026.
- Potential FDA label language regarding BMI cutoff and cardiovascular warnings.
- Any generic competition to the existing Xulane franchise from ANDA filers (Zydus already has an approved generic version).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Viatris Inc 8-K VTRS ·Originating report